JTA NEWS
21 August 2019 - 20 Av 5779 - כ' אב ה' אלפים תשע"ט
JTA NEWS :
Business
AIMA delegation to visit Israel E-mail

A delegation of CEOs from the All India Management Association (AIMA) will visit Israel from 14-18 July to experience first-hand the country’s high-technology innovation ecosystem, and to understand the factors that earned it the ‘Start-up Nation’ tag.

The delegation, the first of its kind visiting Israel, would comprise about 20 members. Amongst the prospective attendees are Sunil Kant Munjal (The Hero Enterprise), TV Mohandas Pai (Manipal Global Education Services) and Preetha Reddy (Apollo Hospitals Enterprise).

“In recent years, the AIMA has been taking CEO delegations to the hotbeds of technological innovation in the US (Silicon Valley) and China. This year, plans are afoot to organise the fourth edition of the delegation to Silicon Valley from 30 September to 3 October,” said AIMA president Hahsharvardhan Neotia.

Regarding policy changes needed to develop similar tech hubs in India, Neotia said the country already has a large tech foothold in Bengaluru and other smaller ones in Delhi NCR, Chennai, and Pune.

Please login or register to see the full article
 
Beijing airport selects Xsight Systems’ solution for runway safety E-mail

Beijing Capital International Airport, one of the busiest airports in the world, which handled over 100 million passengers in 2018, announced recently that it has selected Israel-based Xsight Systems, a global provider of advanced runway sensor-based solutions.

The airport has selected the FOD (Foreign Object Debris) Detection solution for installation on its East Runway. The FOD Detection system will help improve runway safety and capacity by continuously monitoring and detecting any forms of debris or hazards that could interfere with runway operations.

FOD and environmental threats on runways cost the global aviation industry nearly US$12 billion each year. RunWize, Xsight Systems’ Runway Management Solution, prevents many of the FOD incidents, bird strikes and runway excursions, thus increasing runway safety, capacity and efficiency. Amongst the leading airports using this technology are Boston Logan International Airport, Seattle-Tacoma International Airport, Tel-Aviv Ben-Gurion International Airport and Bangkok Suvarnabhumi International Airport. The Israeli Air Force has also adopted RunWize.

Please login or register to see the full article
 
India and Israeli collaborate on research in treatment of OSD Print E-mail

Israel-based Ocular Discovery and the All India Institute of Medical Sciences (AIIMS) in New Delhi have announced the launch of a novel research partnership investigating the mechanism of action of the drug Dipyridamole for various Ocular Surface Disorders (OSD).

Globally prescribed Dipyridamole, which has been used in the treatment of cardiovascular conditions for over 50 years, is already approved and available in Israel for the relief of various ocular conditions and disorders. The drug has shown marked symptomatic benefit in patients with pterygium and related dryeye symptoms, and also offers accessible and efficient delivery of the medication.

The research collaboration, led by Dr T. Velpandian, AIIMS, and Moshe Rogosnitzky, Ocular Discovery, seeks to investigate the effectiveness in the treatment and optimise dosage as a viable treatment option in the country.

(Issue May 2019)

 

 
IDE to build tallest office tower in Ramat Gan E-mail

The Israel Diamond Exchange (IDE) announced on 8 April that it plans to build a 120-storey tower within the Diamond Exchange complex in Ramat Gan Municipality. The tower will be the tallest in Israel and one of the ten tallest buildings in the world.

The building will expand the size of the Diamond Exchange complex to 800,000 sqm, from the 100,000 sqm it currently occupies. Bourse members will allocate some of the new area for use, and the rest will be leased to other business entities.

The project is being promoted by the Ramat Gan Municipality and will include two additional skyscrapers of 88 stories and 77 stories, expanding the number of towers on land owned by IDE to six.

According to Ramat Gan Mayor Carmel Shama-Hacohen, “The new compound will include the flagship tower of the State of Israel and will be the entrance gate to Ramat Gan.”

IDE President Yoram Dvash said: “We have a vision to expand and upgrade the complex to a bustling business centre and a bustling city centre for Ramat Gan, which is no less big and ambitious than the vision of the diamantaires in the 1960s. I was pleased to discover that the mayor is a partner to this vision.”

Please login or register to see the full article
 
South Korean firms invest in Weizmann Institute anti-cancer drug E-mail

An anti-cancer therapy that has been developed by scientists at the Weizmann Institute of Technology will receive a US$10 million investment from a South Korean biopharmaceutical company BioLeaders Corporation, which is traded on the Korea Stock Exchange. This is the firm’s first investment in an Israeli venture.

The Weizmann Institute also announced that a second sum of US$2 million will be invested by Yozma Group Asia, a VC fund, in On-Sight Medical Inc., jointly owned by Yeda Research, New York University (NYU) Medical School and other parties.

The institute said that the two Korean entities have committed to investing in two spinoff companies set up by Yeda Research and Development Co. Ltd., the technology transfer arm of the Weizmann Institute of Science.

BioLeaders Corporation, a clinical-stage biopharmaceutical firm, has signed a Letter of Intent with Yeda for the incorporation of a jointly owned company that will be set up in the coming months to develop the anti-cancer drug.

The drug will be based on the research of Weizmann Institute professors Varda Rotter and Moshe Oren, both of the Molecular Cell Biology Department.

Rotter and Oren were among the first to discover the function of the p53 protein – called the “guardian of the genome”. This protein is mutated or dysfunctional in over two-thirds of all cancers; such malfunctions can cause the cancer to spread faster. The two researchers recently developed a peptide – a small piece of protein – that can restore proper p53 function. The peptide they developed targets the malformed p53, and enters the cell and binds to the protein.

Please login or register to see the full article
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>


Warning: Parameter 1 to modMainMenuHelper::buildXML() expected to be a reference, value given in /home/joomla789/domains/jewishtimesasia.org/public_html/libraries/joomla/cache/handler/callback.php on line 99
Jewish Times Asia is published by Jewish Times Asia Ltd. © Copyright 2019.
Material in the newspaper or on this site may not be used or reproduced in any form or in any way without permission from the editor.
While every effort has been made to ensure the content is true and accurate, the publisher is not responsible for any errors or omissions in the printed text.